Beneficial effects of eicosapentaenoic acid for diabetic patients with arteriosclerosis obliterans.
Okuda
Y
Y
Mizutami
M
M
Tanaka
K
K
Isaka
M
M
Yamashita
K
K
D000368:Aged; D001162:Arteriosclerosis Obliterans / Q000188:drug therapy* / Q000503:physiopathology; D003924:Diabetes Mellitus, Type 2 / Q000503:physiopathology*; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000503:physiopathology; D015118:Eicosapentaenoic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D006439:Hemodynamics; D006801:Humans; D008297:Male
C035276:eicosapentaenoic acid ethyl ester; D015118:Eicosapentaenoic Acid